You searched for "obesity"

218 results found

Button vesicostomy

Poor bladder emptying often requires clean intermittent catheterisation (CIC). In significant numbers of children CIC is not possible for a variety of reasons and an alternative is needed. This paper reviews a single centre’s usage of the vesicostomy button over...

Telemedicine – safe, convenient and economical

I am sure that most, if not all, readers of Urology News will have utilised some form of telemedicine over the last few months during the height of the COVID-19 pandemic. This timely publication from Boston Children’s Hospital precedes the...

Catheter-free wireless ambulatory bladder pressure monitor

Urodynamics (UDS) is a useful physiological test for the assessment of a range of lower urinary tract disorders. A key limitation of standard UDS is its inability to record measurements of bladder pressure, flow, etc. in real-time situations and the...

Fusion Bx 2.0 targeted prostate biopsy solution receives CE Mark

Focal Healthcare, an innovator of image-guided prostate cancer technology, has received CE Mark for its Fusion BxTM 2.0 prostate fusion biopsy solution.

Bupa covers accurate PSE prostate cancer blood test

A new era in prostate cancer detection is emerging with the EpiSwitch® PSE blood test, a highly accurate tool that enhances early diagnosis while significantly cutting false positives. Now covered by Bupa as a pre-biopsy test, PSE has demonstrated 94%...

Is it time for a kidney stress test?

In healthcare, what we measure shapes how we predict outcomes and intervene. For kidney health, traditional tools like estimated glomerular filtration rate (eGFR) provide only a partial picture. Relying solely on eGFR is like judging heart health with a resting...

PARP inhibitors and prostate cancer

The discovery that BRCA1/2-deficient tumour cells are highly sensitive to poly-ADP ribose polymerase (PARP) inhibitors (PARPi) established the foundation of synthetic lethality in metastatic castration-resistant prostate cancer (mCRPC). The TOPARP-A trial confirmed clinical benefit, with PARPi activity largely restricted to...

The PROMIS trial – time for multi-parametric MRI before a first prostate biopsy

Whilst the relatively random process of 12 core transrectal ultrasound guided (TRUS) prostate biopsy remains by far the most widely employed approach to prostate cancer diagnosis in the UK, its flaws as a standalone diagnostic strategy are increasingly apparent. TRUS-biopsy...

Renal oncocytoma: Diagnosis and surveillance strategy

Renal oncocytoma is one of the most common benign renal neoplasms, accounting for around 3–7% of all renal tumours, and up to 18% of all small renal masses (SRMs) measuring less than 4cm [1, 2]. Most oncocytomas are asymptomatic and...

Imaging and surveillance in sporadic renal angiomyolipoma: how and when to monitor effectively

Renal angiomyolipoma (AML) are benign tumours, accounting for approximately 2–3% of all renal neoplasms [1]. Seventy percent of renal AMLs are sporadic, and 20–30% are associated with genetic aetiology. They are composed of smooth muscle, blood vessels, and adipose tissue....

Demanding cases or nightmares in uro-oncology? Sep/Oct 2021

Active surveillance for prostate cancer: missing the boat Case In 2005 a 43-year-old man of Afro-Caribbean ethnicity was referred to our centre for investigation of suspected prostate cancer. Digital rectal exam revealed a firm right lobe, PSA of 2.3ng/ml, prostate...

Prostate cancer series: diagnostics 2

- Click here for Part 1 - A 68-year-old male was referred to the two-week wait prostatic clinic with a serum prostate specific antigen (PSA) of 17. He had no bothersome lower urinary tract symptoms, relevant past medical history or...